我們已在上線！進一步了解

Hyperfine

HYPR

市值 US$8005萬

0.7548 USD

-0.0253

3.24%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.7580

+0.0032

0.42%

1天

-3.24%

5天

-18.84%

1個月

-2.51%

3個月

-23.14%

6個月

-43.25%

今年迄今

-22.1%

1年

-46.85%

5年

-91.79%

10年

-91.79%

關於： Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

員工： 102

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the third quarter 2026 on Monday, November 9, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recordi.

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the third quarter ended September 30, 2026. “Our preliminary third-quarter results demonstrate that execution of our commercial strategy is driving meaningful growth. M.

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

MENLO PARK, Calif.--(BUSINESS WIRE)--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and that Beverly Tang, co-founder and CEO of Starlight Cardiovascular, has received MedtechWOMEN's first-ever Rising Star Award. Both leaders were recognized at the annual MedtechVISION Annual Conference at the Rosewood Sand Hill in Menlo Park, Calif. Since 2016, the Ferolyn Powell Leadership Award has.

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

GUILFORD, Conn.--(BUSINESS WIRE)--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to participate in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th. Management will be hosting in-person meetings. To schedule a meeting with management, please reach out to your Lak.

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices.

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine Q2 Earnings Call Highlights

Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.

Hyperfine Q2 Earnings Call Highlights

查看新聞排名

價格圖表採用Lightweight Charts™實作